Returns | 1W : 3.4% , 1M : -6.2%,1Y : 3.2% |
LT :   |
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
ALKEM LABORATORIES LTD | 3.4% | -6.2% | 3.2% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 0% | 3% | 58.9% |
DR REDDYS LABORATORIES LTD | -0.8% | -3.2% | 43.9% |
DIVIS LABORATORIES LTD | 0.4% | 2.7% | 57.2% |
CIPLA LTD | -0.2% | -4.4% | 86.2% |
BIOCON LTD | 2.6% | 6.3% | 30.6% |
AUROBINDO PHARMA LTD | 2% | -3.6% | 67.6% |
LUPIN LTD | 1.2% | 1.5% | 52.2% |
TORRENT PHARMACEUTICALS LTD | 0.5% | -6.4% | 8% |
Ratio | Value |
---|---|
P/E P/B P/S |
30.87
P/E Calculated based on EPS of 94.28
[ Mar2020 - Consolidated Results ] 5.65
P/B Calculated based on Book Value of 515.21
[ Mar2020 - Consolidated Results ] 4.1
P/S Calculated based on Revenues of 8498.35 Cr
[ TTM - Consolidated Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
96% 18% 23% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |